Compare, Analyse VENUS REMEDIES with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ADCOCK INGRAM
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ADCOCK INGRAM
Jun-14
VENUS REMEDIES/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs126347-   
Low Rs61251-   
Sales per share (Unadj.) Rs301.8103.3-  
Earnings per share (Unadj.) Rs-24.9-26.0-  
Cash flow per share (Unadj.) Rs2.5-21.6-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.381.1-  
Shares outstanding (eoy) m12.34168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 10.7%   
Avg P/E ratio x-3.8-11.5 32.7%  
P/CF ratio (eoy) x36.7-13.9 -265.2%  
Price / Book Value ratio x0.33.7 8.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,15450,448 2.3%   
No. of employees `0000.94.3 21.5%   
Total wages/salary Rs m3933,166 12.4%   
Avg. sales/employee Rs Th4,026.14,061.4 99.1%   
Avg. wages/employee Rs Th425.0737.5 57.6%   
Avg. net profit/employee Rs Th-331.8-1,023.4 32.4%   
INCOME DATA
Net Sales Rs m3,72417,436 21.4%  
Other income Rs m23122 18.4%   
Total revenues Rs m3,74717,558 21.3%   
Gross profit Rs m395-3,021 -13.1%  
Depreciation Rs m338753 45.0%   
Interest Rs m354472 75.0%   
Profit before tax Rs m-275-4,124 6.7%   
Minority Interest Rs m0-11 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32258 12.3%   
Profit after tax Rs m-307-4,393 7.0%  
Gross profit margin %10.6-17.3 -61.2%  
Effective tax rate %-11.5-6.2 183.7%   
Net profit margin %-8.2-25.2 32.7%  
BALANCE SHEET DATA
Current assets Rs m2,63812,770 20.7%   
Current liabilities Rs m2,3057,185 32.1%   
Net working cap to sales %8.932.0 27.9%  
Current ratio x1.11.8 64.4%  
Inventory Days Days135111 122.1%  
Debtors Days Days46124 37.4%  
Net fixed assets Rs m4,8717,444 65.4%   
Share capital Rs m12381 152.4%   
"Free" reserves Rs m3,4960-   
Net worth Rs m3,61913,685 26.4%   
Long term debt Rs m1,3744,809 28.6%   
Total assets Rs m7,50925,852 29.0%  
Interest coverage x0.2-7.7 -2.9%   
Debt to equity ratio x0.40.4 108.1%  
Sales to assets ratio x0.50.7 73.5%   
Return on assets %0.6-15.2 -4.2%  
Return on equity %-8.5-32.1 26.4%  
Return on capital %1.6-19.8 -8.0%  
Exports to sales %00-   
Imports to sales %13.90-   
Net fx Rs m-5170-   
CASH FLOW
From Operations Rs m5141,488 34.6%  
From Investments Rs m-123-457 26.9%  
From Financial Activity Rs m-3874,365 -8.9%  
Net Cashflow Rs m45,396 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.79 Rs / ZAR

Compare VENUS REMEDIES With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: PANACEA BIOTECH  IPCA LABS  ELDER PHARMA  PIRAMAL ENTERPRISES  SHASUN PHARMA  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound? (The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks (Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 17, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS